SecProbe.io

CORRESP
 1
 filename1.htm

 APREA THERAPEUTICS,
INC.

 3805 Old Easton Road

 Doylestown, PA 18902

 April 27, 2026

 VIA EDGAR

 Securities and Exchange Commission

 Division of Corporation Finance

 Office of Life Sciences

 100 F Street, N.E.

 Washington, D.C. 20549

 Attention: Doris Stacey Gama

 Re:
 Aprea Therapeutics, Inc.

 Registration Statement on Form S-3

 File No. 333-295247

 Request for Acceleration

 Ladies and Gentlemen:

 Pursuant
to Rule 461 promulgated under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the " Registrant ") hereby
requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-295247), so
that it may become effective at 5:00 p.m. Eastern Time on April 29, 2026, or as soon as practicable thereafter, or at such later time
as the Registrant or its counsel may orally request via telephone call to the staff.

 The
cooperation of the staff in meeting the timetable described above is very much appreciated.

 Please
call Patrick O'Malley, Esq. of DLA Piper LLP (US), counsel to the Company, at (206) 839-4831, with any comments or questions
regarding the Registration Statement.

 Very truly yours,

 APREA THERAPEUTICS, INC.

 By:
 /s/ Oren Gilad

 Name:
 Oren Gilad

 Title:
 Chief Executive Officer

 cc:
 Fahd Riaz, Esq., DLA Piper LLP (US)

 Dylan Caplan, Esq., DLA Piper LLP (US)

April 27, 2026
Oren Gilad
Chief Executive Officer
Aprea Therapeutics, Inc.
3805 Old Easton Road
Doylestown, PA 18902
Re: Aprea Therapeutics, Inc.
Registration Statement on Form S-3
Filed April 22, 2026
File No. 333-295247
Dear Oren Gilad:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Patrick O'Malley, Esq.

CORRESP
1
filename1.htm

SIDLEY AUSTIN LLP

787 SEVENTH AVENUE

NEW YORK, NY 10019

+1 212 839 5300

+1 212 839 5599 FAX

AMERICA  ·  ASIA PACIFIC  ·  EUROPE

GLEVIN@SIDLEY.COM

+1 212 839 5776

September 25, 2019

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Healthcare & Insurance

100 F Street, N.E.

Washington, D.C.  20549-3720

Attention:

Sonia Bednarowski

Dietrich King

Keira Nakada

Kevin Vaughn

Re:                             Aprea Therapeutics, Inc.

Amendment No. 1 to Registration Statement on Form S-1

Filed September 23, 2019

File No. 333-233662

Ladies and Gentlemen:

On behalf of our client, Aprea Therapeutics, Inc. (the “Company”), we submit this letter (the “Letter”) in response to comments received from the staff (the “Staff”) of the U.S. Securities and Exchange Commission (the “Commission”) by letter dated September 24, 2019 (the “Comment Letter”), relating to the Company’s Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-233662) (the “Registration Statement”), filed with the Commission on September 23, 2019.  We are concurrently submitting via EDGAR this letter and a second amendment to the Registration Statement.

In this Letter, we have recited the prior comment from the Staff in italicized, bold type and have followed the comment with the Company’s response in ordinary type.

Exhibits and financial statement schedules

Exhibits

Exhibit 10.3, page II-4

1.                                      We note your disclosure in Exhibit 10.3 that “[c]ertain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.” If you intend to redact information pursuant to Item 601(b) of Regulation S-K, please revise the language in Exhibit 10.3 to state that certain identified information has been

Sidley Austin (NY) LLP is a Delaware limited liability partnership doing business as Sidley Austin LLP and practicing in affiliation with other Sidley Austin partnerships.

excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

The Company respectfully advises the Staff that it has revised the language in Exhibit 10.3 to state that certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Furthermore, the Company respectfully advises the Staff that it has removed the inadvertently-inserted brackets from certain “***” on page 7 of Exhibit 10.3 because such “***” were included in the body of the original agreement and are not representative of redactions being made by the Company.

*       *       *       *       *

2

We thank you in advance for your consideration of the foregoing. If you have any questions, please direct them to me at (212) 839-5776 or glevin@sidley.com or, alternatively, Istvan Hajdu at (212) 839-5651 or ihajdu@sidley.com.

Very   truly yours,

/s/   Geoffrey Levin

Geoffrey   W. Levin

cc:

Christian   S. Schade, Aprea Therapeutics, Inc.

Samir   A. Gandhi, Sidley Austin LLP

Istvan   A. Hajdu, Sidley Austin LLP

Richard   D. Truesdell, Jr., Davis Polk & Wardwell LLP

Derek   Dostal, Davis Polk & Wardwell LLP

3